cas 847199-90-0|| where to buy (R)-tert-butyl (1-(1H-indol-3-yl)propan-2-yl)carbamate

Produktname:(R)-tert-butyl (1-(1H-indol-3-yl)propan-2-yl)carbamate

IUPAC Name:tert-butyl N-[(2R)-1-(1H-indol-3-yl)propan-2-yl]carbamate

Packungseinheit	Verfügbarer Vorrat	Preis($)	Menge
CM327924-50g	4-5 Weeks	ƥƃȺȐ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 847199-90-0 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:847199-90-0; Molekulare Formel:C16H22N2O2; Schmelzpunkt:-; SMILES-Code:O=C(OC(C)(C)C)N[C@H](C)CC1=CNC2=C1C=CC=C2; Dichte:

: Katalognummer:CM327924; Molekulargewicht:274.36; Siedepunkt:; Mdl-Nr.:; Lagerung:

: Giredestrant; Giredestrant (GDC-9545) is under development by Roche/Genentech. Giredestrant is a potent, next generation investigational selective oestrogen receptor (SERD) with best-in-class potential. In the phase 2 coopERA trial, postmenopausal patients with untreated ER+/HER2- early breast cancer were randomly assigned to receive neoadjuvant combination therapy with palbociclib and giredestrant or anastrozole, followed by surgical intervention within 14 days. The tumor biomarker Ki67 of the patients was ≥ 5% when they were enrolled in the group. The analysis showed that patients receiving giredestrant combination therapy (mean Ki67 reduction of 80%) had a greater mean reduction in Ki67 levels from baseline at week 2 compared with anastrozole combination therapy (mean Ki67 reduction of 67%). The pivotal phase 3 trial of giredestrant is recruiting patients and preliminary data is expected in 2025.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.